F10 and chronic kidney disease: A prospective multicenter noninterventional real-world European registry is currently ongoing (Factor XA-Inhibition in REnal Patients with Non-valvular Atrial Fibrillation-XARENO) collecting clinical data from 2500 patients with AF and CKD (eGFR 15–49 mL/min) receiving anticoagulation at the discretion of the clinician based on the currently available guidelines (Rivaroxaban, VKA or no OAC) with the aim to assess CKD progression and clinical outcomes in regards to anticoagulation strategies in everyday clinical practice (ClinicalTrials.gov identifier NCT02663076).